These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23394438)

  • 1. Meningioma 1 (MN1) expression: refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML).
    Aref S; Ibrahim L; Morkes H; Azmy E; Ebrahim M
    Hematology; 2013 Sep; 18(5):277-83. PubMed ID: 23394438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.
    Heuser M; Beutel G; Krauter J; Döhner K; von Neuhoff N; Schlegelberger B; Ganser A
    Blood; 2006 Dec; 108(12):3898-905. PubMed ID: 16912223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
    Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
    J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.
    Carturan S; Petiti J; Rosso V; Calabrese C; Signorino E; Bot-Sartor G; Nicoli P; Gallo D; Bracco E; Morotti A; Panuzzo C; Gottardi E; Frassoni F; Saglio G; Cilloni D
    Oncotarget; 2016 Nov; 7(45):74082-74096. PubMed ID: 27765915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML.
    Heuser M; Argiropoulos B; Kuchenbauer F; Yung E; Piper J; Fung S; Schlenk RF; Dohner K; Hinrichsen T; Rudolph C; Schambach A; Baum C; Schlegelberger B; Dohner H; Ganser A; Humphries RK
    Blood; 2007 Sep; 110(5):1639-47. PubMed ID: 17494859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
    Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
    Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia.
    Haferlach C; Kern W; Schindela S; Kohlmann A; Alpermann T; Schnittger S; Haferlach T
    Genes Chromosomes Cancer; 2012 Mar; 51(3):257-65. PubMed ID: 22072540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refinement of Risk-Stratification of Cytogenetically Normal Acute Myeloid Leukemia Adult Patients by MN1 Expression.
    Ningombam A; Verma D; Kumar R; Singh J; Ali MS; Pandey AK; Singh I; Bakhshi S; Sharma A; Pushpam D; Palanichamy JK; Tanwar P; Ranjan Singh A; Chopra A
    Asian Pac J Cancer Prev; 2024 Jul; 25(7):2283-2289. PubMed ID: 39068559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
    Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W
    Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
    Schwind S; Marcucci G; Kohlschmidt J; Radmacher MD; Mrózek K; Maharry K; Becker H; Metzeler KH; Whitman SP; Wu YZ; Powell BL; Baer MR; Kolitz JE; Carroll AJ; Larson RA; Caligiuri MA; Bloomfield CD
    Blood; 2011 Oct; 118(15):4188-98. PubMed ID: 21828125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
    Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
    Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MN1 and PTEN gene expression in acute myeloid leukemia.
    Zayed RA; Eltaweel MA; Botros SK; Zaki MA
    Cancer Biomark; 2017; 18(2):177-182. PubMed ID: 27983532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype.
    Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N
    Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
    Jentzsch M; Bill M; Grimm J; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
    Ann Hematol; 2020 Oct; 99(10):2417-2427. PubMed ID: 32862286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
    Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
    Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
    Damm F; Oberacker T; Thol F; Surdziel E; Wagner K; Chaturvedi A; Morgan M; Bomm K; Göhring G; Lübbert M; Kanz L; Fiedler W; Schlegelberger B; Heil G; Schlenk RF; Döhner K; Döhner H; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Feb; 29(6):682-9. PubMed ID: 21205756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
    Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.